Lehigh Valley Health Network (LVHN) has announced that HNL Lab Medicine President and Chief Executive Officer Atty. Matthew R. Sorrentino has retired this fall to be succeeded by HNL Lab Medicine Board of Directors Chair and LVHN Board of Trustees Vice Chair Martin K. Till. Sorrentino’s retirement was effective Oct. 15. Till started in the new post Sept. 1.

“HNL Lab Medicine has prospered under Matt’s leadership and commitment to excellence to become the preeminent lab medicine company in the region,” said Brian A. Nester, DO, MBA, President and Chief Executive Officer, LVHN.

Sorrentino was involved in the founding of HNL and served for more than 20 years as HNL’s Board Secretary. Sorrentino assumed the top job at HNL Lab Medicine in May 2019. He served as outside counsel for both organizations for almost 25 years and was LVHN Senior Vice President and Chief Legal Officer in recent years.

“It was my great honor and privilege to lead a team of dedicated and selfless professionals at HNL, particularly through our community’s fierce battle against COVID-19,” Sorrentino said.

Sorrentino, an Army veteran, was Chairman and Managing Partner of Norris, McLaughlin & Marcus P.A., and Chairman of Tallman, Hudders & Sorrentino, P.C, prior to joining LVHN. He continues as a consultant for LVHN and HNL Lab Medicine. Sorrentino will no longer be an HNL Lab Medicine Board member.

Till has been part of the LVHN board since 2004 and on the HNL board since 2013. Till resigned from the board positions. Kathy O’Brien, a member of the LVHN Board and Vice Chair of the HNL Board, replaced Till as Board Chair of HNL.

Till, also an Army veteran, left his job as a partner in ClearLine Development, a real estate development and construction management firm based in the Lehigh Valley, to take the helm at HNL Lab Medicine. For 14 years, from 1998-2012, Till was Chief Executive Officer, President and Publisher of The Express-Times newspaper and lehighvalleylive.com.